

Xing-Sheng Hu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5579251/xing-sheng-hu-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26

papers

142

citations

6

h-index

11

g-index

30

ext. papers

238

ext. citations

3.9

avg, IF

2.59

L-index

#	Paper	IF	Citations
26	Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 556-567	8.9	27
25	Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, 247-254	4.9	25
24	Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 2427-2433	4.9	19
23	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. <i>PLoS ONE</i> , 2015 , 10, e0142500	3.7	11
22	Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 3162-3171	12.9	8
21	Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. <i>Investigational New Drugs</i> , 2019 , 37, 731-737	4.3	6
20	Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: A retrospective analysis. <i>Thoracic Cancer</i> , 2017 , 8, 482-488	3.2	5
19	Different responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report. <i>Oncology Letters</i> , 2019 , 18, 5085-5090	2.6	4
18	The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms. <i>Cancer Biology and Medicine</i> , 2021 ,	5.2	4
17	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 6	22.4	3
16	Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial. <i>Thoracic Cancer</i> , 2018 , 9, 693-698	3.2	3
15	Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. <i>Thoracic Cancer</i> , 2020 , 11, 3501-3509	3.2	3
14	Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018 , 9, 805-813	3.2	3
13	Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis. <i>Thoracic Cancer</i> , 2021 , 12, 2749-2757	3.2	3
12	Population Pharmacokinetics and Exposure-Safety Relationship of Paclitaxel Liposome in Patients With Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 1731	5.3	2
11	Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. <i>Thoracic Cancer</i> , 2021 , 12, 2585-2593	3.2	2
10	Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. <i>Thoracic Cancer</i> , 2021 , 12, 2924-2932	3.2	2

9	The clinical significance of RET gene fusion among Chinese patients with lung cancer.. <i>Translational Cancer Research</i> , 2020 , 9, 6455-6463	0.3	1
8	Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018 , 9, 1716-1724	3.2	1
7	Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2021 , 12, 2360-2368	3.2	1
6	Hyaluronic Acid Correlates With Bone Metastasis and Predicts Poor Prognosis in Small-Cell Lung Cancer Patients.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 785192	5.7	
5	CD56+ lymphoepithelioma-like carcinoma of the lung: A case report and literature review. <i>World Journal of Clinical Cases</i> , 2020 , 8, 1257-1264	1.6	
4	Phase I study of apatinib combined with docetaxel in EGFR-negative advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21184-e21184	2.2	
3	BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21108-e21108	2.2	
2	Progression pattern and post-progression treatment of furmonertinib (AST2818) in EGFR T790M mutation positive NSCLC patients: A post-hoc analysis from a multicenter, single-arm study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21071-e21071	2.2	
1	Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma. <i>Chinese Medical Journal</i> , 2021 , 134, 2119-2121	2.9	